Key Account · GLP-1 / Cardiometabolic · 2025–2026
Novo Nordisk
Equals 5 · NPI-Matched HCP Social Media + Clinician Education · National Scale
Relationship Since
2025
Direct & Agency · CMI Media Group
Brands Activated
4
6 won deals · 4 brands
Won Deals
6
2025–2026 · All brands
Active Programs
3
Wegovy NBE · Wegovy CU · Ozempic CU
NPI Match Rate
90%++
vs. industry avg 40–60%
Executive Snapshot · Novo Nordisk GLP-1 Portfolio
Key Account
May 2026
Equals 5 delivers national-scale NPI-matched HCP targeting across Novo Nordisk's GLP-1 and cardiometabolic portfolio — reaching 100K+ endocrinologists, PCPs, and obesity medicine specialists with 90%++ match rates and physician-level analytics across the GLP-1 franchise.
4
Brands Activated
100K+
HCP Universe
90%++
NPI Match Rate
6
Programs Delivered
What EQ5 Does
Deterministic NPI-matching at national scale across Meta and LinkedIn — no modeled lookalikes, no wasted impressions. Every impression is verified against a physician NPI, with sFTP reporting, CRM integration, and physician-level engagement scoring included at no extra cost. Novo Nordisk's GLP-1 portfolio runs on a shared NPI infrastructure, enabling cross-brand sequencing without duplicating list costs.
Why It Matters for Wegovy
The GLP-1 market is the most competitive category in pharma. Wegovy's MACE cardiovascular risk reduction indication has broadened the prescriber universe to cardiologists — a specialty EQ5 already reaches. Physician-level engagement scoring shows exactly which endocrinologists, PCPs, and obesity medicine specialists engage with weight management messaging, allowing the Novo Nordisk team to prioritize outreach and MSL visits where digital engagement is highest.
Programs
Brand Program Summary
| Brand | Indication | Job Code | Budget | Status | Channels |
|---|---|---|---|---|---|
| Wegovy | Chronic Weight Management / MACE | eq5-1362 / eq5-1311 | — | Active | NPI Social (NBE) · Clinician Education Network |
| Ozempic | Type 2 Diabetes / Glycemic Control | eq5-1155 / eq5-1312 | — | Active | NPI Social (GM) · Clinician Education Network |
| Rybelsus | Type 2 Diabetes (oral semaglutide) | eq5-1156 | — | Complete | NPI Social (GM) |
| Nexlizet | LDL-C Reduction / Cardiometabolic | eq5-1182 | — | Complete | Medical Publisher Network |
Wegovy
Chronic Weight Management / Cardiovascular Risk Reduction (MACE)
NPI-Matched Social (NBE) · Clinician Education Network ·
View Wegovy Program →
Ozempic
Type 2 Diabetes / Glycemic Control
NPI-Matched Social (GM) · Clinician Education Network
Audience
NPI Match Rate
90%++
vs. industry avg 40–60%
HCP Universe
100K+
National scale · 4 specialties
Geographic Scope
National
All 50 states · Major metro + rural
List Deduplication
Enabled
Cross-brand · No duplicate delivery
HCP Specialty Breakdown
| Specialty | Share | Primary Programs | Rationale |
|---|---|---|---|
| Endocrinologists | ~40% | Wegovy · Ozempic · Rybelsus | Core GLP-1 prescribers — highest Rx volume |
| Primary Care Physicians | ~35% | Wegovy · Ozempic | Fastest-growing GLP-1 prescriber class |
| Obesity Medicine Specialists | ~15% | Wegovy | High-intent weight management segment |
| Cardiologists | ~10% | Wegovy (MACE) · Nexlizet | Expanding segment post-MACE indication |
Channels
LinkedIn
Primary HCP Engagement
Wegovy NBE · Ozempic GM · Highest professional identity precision
Meta
Scale + Awareness
Wegovy NBE · Ozempic GM · National reach at scale · NPI-matched
Clinician Education Network
Peer-Trusted Clinical Education
Wegovy CU · Ozempic CU · Point-of-care HCP touchpoint
Medical Publisher Network
Specialist Education
Nexlizet · Cardiometabolic specialist reach
Tier 1
High Engagers
90+ engagement score · Priority MSL list
Tier 2
Active Prescribers
60–89 · Regular impression frequency
Tier 3
Awareness Reached
30–59 · Sustained nurture cadence
Tier 4
In-Universe
<30 · Matched · Not yet engaged
Measurement
Program KPIs & Reporting
| KPI | Target | Delivery Method | Frequency |
|---|---|---|---|
| NPI Match Rate | 90%++ | sFTP · CRM Integration | Monthly |
| Identified Impressions | Per IO | sFTP Report | Weekly |
| HCP Reach | 100K+ universe | Physician-level report | Monthly |
| Engagement Scoring | Tiered 1–4 | Segmented HCP list | Quarterly |
| CTR by Channel | Meta + LinkedIn split | Dashboard + sFTP | Weekly |
| Cross-Brand Deduplication | Enabled | Wegovy / Ozempic shared list | Ongoing |
| Full Funnel Analytics | Included | No additional cost | Per program |
Timeline
Program Milestones
| Date | Milestone | Deal / Brand | Value | Status |
|---|---|---|---|---|
| Apr 2025 | Ozempic GM Program Launch | EQ5-1155 · Ozempic | — | Complete |
| Apr 2025 | Rybelsus GM Program Launch | EQ5-1156 · Rybelsus | — | Complete |
| Apr 2025 | Nexlizet Clinician Education Program | EQ5-1182 · Nexlizet | — | Complete |
| Jan 2026 | Wegovy Clinician Education Program | EQ5-1311 · Wegovy | — | Active |
| Jan 2026 | Ozempic Clinician Education Program | EQ5-1312 · Ozempic | — | Active |
| Apr 2026 | Wegovy NBE Social Media Program Go-Live | EQ5-1362 · Wegovy | — | Active |
| Q2 2026 | Q2 Business Review · Wegovy NBE | EQ5-1362 · All brands | — | Scheduled |
| 2026+ | Portfolio Expansion Discussions | Ozempic NBE · CagriSema | TBD | Pipeline |
Your EQ5 Team
Client Contact
Account Details
Client
Novo Nordisk
Status
Key Account
Relationship Since
2025
Agency
CMI Media Group
Therapeutic
Endocrinology · GLP-1 · Cardiometabolic · T2D
Active Programs
Wegovy · Ozempic · Rybelsus · Nexlizet
NPI Match Rate
90%++
Portal Stage
Stage 3 of 3
Pipedrive Org
ID 32
Upcoming Touchpoints
Q2 2026 — Wegovy NBE Review
EQ5-1362 · Performance review + Q3 planning
Ozempic NBE Expansion
Same NPI infrastructure · Cross-brand expansion opportunity
2026 Portfolio QBR
Cross-brand Wegovy + Ozempic sequencing review